Mentions
Extended reach
Total likes
Video views
AI synopsis
The group of mentions collectively demonstrates high agreement on the positive findings of the ACHIEVE-3 trial, with tone emphasizing innovations like the oral small-molecule GLP-1 receptor agonist. For example, many mentions describe orforglipron as 'more effective' and highlight its potential to replace injections, reflecting both high interest and perceived impact. The detailed comparison of HbA1c reductions and safety concerns indicates deep engagement and broad recognition of its potential to change treatment paradigms.
Many mentions highlight that orforglipron was non-inferior or superior to semaglutide, reflecting strong support for the study results.
Mentions use phrases like 'innovative,' 'breakthrough,' and compare efficacy directly, indicating high engagement and curiosity.
Mentions include detailed comparisons of HbA1c reductions and safety profiles, showing deep analysis and aligned discussion of methods and implications.
Numerous mentions cite the approval and superior results, suggesting significant influence on treatment options and clinical practice.
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial https://t.co/MvJPOzDZoM https://t.co/lRLjvgA5v7
(626/347) #論文マラソン オルフォルグリプロン(傾向GLP-1RA) VS 経口セマグルチドと比較することです。 ACHIEVE-3 52週間RCT HbA1c・体重の平均変化量はオルフォルグリプロンが非劣勢・優勢だった。 有害事象による試験治療はオルフォルグリプロン群の方が多かった。 https://t.co/Yop4xoKWq0
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial In individuals with type 2 diabetes inadequately controlled with metformin, orforglipron 12 mg and 36 mg was non-inferior and superior to semaglutide 7 mg and 14 mg with respect to the mean change in HbA1c from baseline to 52 weeks. #Cardiology #MedTwitter #CardioTwitter #HeartHealth #Healthcare @DLBHATTMD @CMichaelGibson @TheLancetEndo @TheLancet @iamritu @hvanspall @DrMarthaGulati https://t.co/ah5Q0eEO3e
➡️@PubMedOnline Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with DM2 (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial Julio Rosenstock et al. Lancet. 2026. https://t.co/V3o8itAu44 https://t.co/sQCIkNExF1
"Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial." Publié ce jour dans @thelancet.com #medSky #EndoSky www.thelancet.com/journals/lan...
RT @drbennisahmed: Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIE…
The study found that both doses of orforglipron demonstrated non-inferiority to oral semaglutide in reducing HbA1c levels after 52 weeks in adults with type 2 diabetes. The safety profile was consistent with…
The oral GLP-1 pill orforglipron (Foundayo) outperformed oral semaglutide in blood sugar control and weight reduction during the ACHIEVE-3 trial. However, tolerability issues and lack of cardiovascular data are…
The FDA approved the oral GLP-1 medication orforglipron (Foundayo) on April 1, 2026. This first oral GLP-1 tablet requires no food, water, or timing restrictions. Clinical trials show it is as effective as semaglutide…
Orforglipron is now FDA-approved as Foundayo, making it one of the first serious oral small-molecule GLP-1 weight loss medications. In this video, we analyze how it functions, compare it to injectable GLP-1 agonists…
This study evaluates the efficacy and safety of once-daily oral orforglipron compared to oral semaglutide. Both doses of orforglipron demonstrated non-inferiority in reducing HbA1c levels over 52 weeks, supporting its…
Orforglipron (Foundayo), an oral GLP-1 agonist, has now been approved, marking a significant advancement in weight loss therapies. Unlike other formulations, it is a non-peptide small-molecule drug that offers potential…
Both doses of orforglipron demonstrated non-inferiority to oral semaglutide in reducing HbA1c levels over 52 weeks, with similar safety profiles. This study highlights the efficacy, tolerability, and potential clinical…
Orforglipron, a small molecule oral GLP-1 receptor agonist, offers advantages over peptide-based semaglutide, including better absorption and production. The ACHIEVE-3 trial shows non-inferiority in HbA1c reduction…
RT @redGDPS: ➡️@PubMedOnline Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with DM2 (ACHIEV…
RT @redGDPS: ➡️@PubMedOnline Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with DM2 (ACHIEV…
RT @redGDPS: ➡️@PubMedOnline Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with DM2 (ACHIEV…
➡️@PubMedOnline Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with DM2 (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial Julio Rosenstock et al. Lancet. 2026. https://t.co/V3o8itAu44 https://t.co/sQCIkNExF1
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial - The Lancet https://t.co/Gnwi4OVmlH - amazing and I think it's soon
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial - The Lancet www.thelancet.com/journals/lan...
RT @DiegoBellido2: Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIE…
RT @DiegoBellido2: Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIE…
RT @DiegoBellido2: Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIE…
RT @DiegoBellido2: Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIE…
"Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial." Publié ce jour dans @thelancet.com #medSky #EndoSky www.thelancet.com/journals/lan...
RT @DiegoBellido2: Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIE…
RT @DiegoBellido2: Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIE…
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial https://t.co/MvJPOzDZoM https://t.co/lRLjvgA5v7
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial - The Lancet https://t.co/qysmWVGMtz
[Articles] Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial https://t.co/wdP4FiFa6I
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3) https://t.co/AeoFfIHdET
オルフォルグリプロンを経口セマグルチドと比較。非劣性は達成した。 ACHIEVE-3試験 https://t.co/1xm8ecQOLw
(626/347) #論文マラソン オルフォルグリプロン(傾向GLP-1RA) VS 経口セマグルチドと比較することです。 ACHIEVE-3 52週間RCT HbA1c・体重の平均変化量はオルフォルグリプロンが非劣勢・優勢だった。 有害事象による試験治療はオルフォルグリプロン群の方が多かった。 https://t.co/Yop4xoKWq0
RT @drbennisahmed: Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIE…
RT @drbennisahmed: Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIE…
RT @drbennisahmed: Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIE…
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial In individuals with type 2 diabetes inadequately controlled with metformin, orforglipron 12 mg and 36 mg was non-inferior and superior to semaglutide 7 mg and 14 mg with respect to the mean change in HbA1c from baseline to 52 weeks. #Cardiology #MedTwitter #CardioTwitter #HeartHealth #Healthcare @DLBHATTMD @CMichaelGibson @TheLancetEndo @TheLancet @iamritu @hvanspall @DrMarthaGulati https://t.co/ah5Q0eEO3e
Link: www.thelancet.com/journals/lan... #GISky #PedsSky #EMSky #SciSky #GLP
expert reaction to ACHIEVE-3 trial results about efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes www.sciencemediacentre.org/expert-react...
expert reaction to ACHIEVE-3 trial results about efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes https://t.co/3IxXlMkRVg
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre ...
A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Adult Participants ...
... Efficacy and Safety of Once daily Oral Orforglipron Compared with Placebo in Adults Participants with Type 2 Diabetes and Inadequate Glycemlc Control with ...
... Efficacy and Safety of Once-Daily Oral Orforglipron Compared with Placebo in Individuals with Overweight at Risk of Development of Obesity-Related Complications ...
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre ...
Lancet. Published online February 25, 2026. doi:10.1016/S0140-6736(26)00202-3 · Current Consultant Issue · Previous Issues · Early View. Research Summaries.
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre ...
... doi:10.1016/S0140-6736(26)00202-3. Quality in Sport. Downloads. PDF. Published. 2026-05-30. How to Cite. 1. BLECHARCZYK, Małgorzata, JAKIMOWICZ ...
Lancet 2026; doi:10.1016/S0140-6736(26)00202-3 · Lancet 2026; doi:10.1016/S0140-6736(26)00360-0. Sharing Print. Related topics. GLP-1 Receptor Agonists ...
The Lancet https://doi.org/10.1016/S0140-6736(26)00202-3. 2. Yasgur, B.S. (2026) New Oral GLP-1 Beats Oral Semaglutide for A1c, Weight Loss. Medscape ...
10.1016/S0140-6736(26)00202-3. More actions. Article preview; Recommended ... 26; p
2026 Feb 26:S0140-6736(26)00202-3. doi: 10.1016/S0140-6736(26)00202. PubMed Abstract available; BONACA MP, Nordanstig J, Ludvik B, Videmark A, et al. Response ...
10.1016/S0140-6736(26)00202-3. More actions. Article. Summary. Background. Orforglipron is a novel non-peptide (GLP-1) receptor agonist designed for daily oral ...
Published February 26, 2026. DOI: 10.1016/S0140-6736(26)00202-3 External LinkAlso available on ScienceDirect External Link. Copyright: © 2026 Elsevier Ltd.
doi: 10.1016/S0140-6736(26)00202-3 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #semaglutida #diabetes #GLP1 ...
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type... In individuals with type 2 diabetes inadequately ...
https://doi.org/10.1016/S0140-6736(26)00202-3 Anche la Company, Eli Lilly, ha annunciato i risultati dettagliati di ACHIEVE-3. https://investor.lilly. com ...
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre ...
expert reaction to ACHIEVE-3 trial results about efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 ...
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre ...
... 10.1016/S0140-6736(26)00202-3 [751] doi:10.1002/cpdd.1594 [752] doi:10.1073/pnas.2014879117 [753] doi:10.1016/j.ebiom.2026.106121.
DOI: 10.1016/S0140-6736(26)00202-3. som original - Dra. Luíza Vercelli. 4Curtidas. 1Comentários. 0Compartilhamentos. luizavercelli. Dra. Luíza ...
doi: 10.1016/S0140-6736(26)00202-3. Epub 2026 Feb 26. PMID: 41765029. * Tan HC, Dampil OA, Marquez MM. Efficacy and Safety of Semaglutide ...
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a ...
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a ...
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a ...
26m. Paula Mesquita. 2d ... DOI: 10.1016/S0140-6736(26)00202-3. Você acha que a metformina ...
DOI: 10.1016/S0140-6736(26)00202-3. Você acha que a metformina continuará ocupando o mesmo espaço nos próximos 10 anos? Salve e ...
... 10.1016/S0140-6736(26)00202-3. 4. Aroda VR, Aberle J, Bardtrum L, et al. Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg ...
doi:10.1016/S0140-6736(26)00202-3. Wharton S, et al. N Engl J Med. 2025;393:1796-1806. doi:10.1056/NEJMoa2511774. #foundays #glp #diabetes ...
... 10.1016/S0140-6736(26)00202-3 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #semaglutida #diabetes ...
https://doi.org/10.1016/S0140-6736(26)00202-3. Epub 2026 Feb 26. PMID: 41765029. Aroda V, Aberle J, Bardtrum L, et al. Efficacy and safety ...
https://doi.org/10.1016/S0140-6736(26)00202-3. Epub 2026 Feb 26. PMID: 41765029. Aroda V, Aberle J, Bardtrum L, et al. Efficacy and safety ...
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a ...
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a ...
... 10.1016/S0140-6736(26)00202-3 ℹ️ Contenido educativo. No sustituye ... 26 (criterio de valoración principal) y en la semana 36 ...
doi: 10.1016/S0140-6736(26)00202-3 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #semaglutida ...
; et al. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a ...
DOI: 10.1016/S0140-6736(26)00202-3. som original - Dra. Luíza Vercelli. 4Curtidas. 1Comentários. 0Compartilhamentos. luizavercelli. Dra. Luíza ...
... 10.1016/S0140-6736(26)00202-3. Você acha que a metformina continuará ocupando o mesmo espaço nos próximos 10 anos? Salve e compartilhe ...
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a ...
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a ...
DOI: 10.1016/S0140-6736(26)00202-3. som original - Dra. Luíza Vercelli. 4Curtidas. 1Comentários. 0Compartilhamentos. luizavercelli. Dra. Luíza ...
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type... In individuals with type 2 ...
The landscape of peptide Efficacy and safety of once-daily oral orforglipron compared with oral research and fitness optimization has ...
... 10.1016/S0140-6736(26)00202-3 #ACHIEVE3 #Orforglipron #Semaglutida #GLP1 #DiabetesTipo2 EfectosAdversos Seguridad MedicinaBasadaEnEvidencia ...
2026;407:1147-1160. DOI: 10.1016/S0140-6736(26)00202-3 #ACHIEVE3 #Orforglipron #Semaglutida #GLP1 #DiabetesTipo2 EfectosAdversos Seguridad ...
... Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3). Lancet. 2026 ...
DOI: 10.1016/S0140-6736(26)00202-3 #ACHIEVE3 #Orforglipron #Semaglutida #GLP1 #DiabetesTipo2 HbA1c PérdidaDePeso MedicinaBasadaEnEvidencia.
doi:10.1016/S0140-6736(26)00202-3 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #semaglutida #diabetes ...
DOI: 10.1016/S0140-6736(26)00202-3 #ACHIEVE3 #Orforglipron #Semaglutida #GLP1 #DiabetesTipo2 HbA1c PérdidaDePeso MedicinaBasadaEnEvidencia ...
New real world target trial emulation finds that, among adults with overweight or obesity and type 2 diabetes, tirzepatide and injectable ...
DOI:10.1016/S0140-6736(26)00202-3. Authors: Julio Rosenstock at The ... 26][27][28][29][30][31][32][33][34][35][36 ...
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a ...
doi:10.1016/S0140-6736(26)00202-3 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #semaglutida #diabetes ...
... Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3) Pacientes con ...
DOI: 10.1016/S0140-6736(26)00202-3. som original - Dra. Luíza Vercelli. 4Curtidas. 1Comentários. 0Compartilhamentos. luizavercelli. Dra. Luíza ...
... 10.1016/S0140-6736(26)00202-3 Additional citations linked in the companion blog post. CHAPTERS: 0:00 The pill that beat the pill 0:28 ...
DOI: 10.1016/S0140-6736(26)00202-3. som original - Dra. Luíza Vercelli. 4Likes. 1Comments. 0Shares. pauzunigaoficial. Dra. Pau Zúñiga.
doi:10.1016/S0140-6736(26)00202-3 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #semaglutida #diabetes ...
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a ...
... 10.1016/S0140-6736(26)00202-3 [751] doi:10.1002/cpdd.1594 [752] doi:10.1073/pnas.2014879117 [753] doi:10.1016/j.ebiom.2026.106121.
... 6736, https://doi.org/10.1016/S0140-6736(26)00202-3. Unit Footer. College of Pharmacy. Website Feedback · Contact Us · Accreditation. Follow Us.
Lancet. 2026;doi:10.1016/S0140-6736(26)00202-3. Data from both trials were presented at the American Diabetes Association ...
... 10.1016/S0140-6736(26)00202-3 [751] doi:10.1002/cpdd.1594 [752] doi:10.1073/pnas.2014879117 [753] doi:10.1016/j.ebiom.2026.106121".
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a ...
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a ...
Efficacy and safety of once-daily oral orforglipron compared with oral ...
... 10.1016/S0140-6736(26)00202-3 [751] doi:10.1002/cpdd.1594 [752] doi:10.1073/pnas.2014879117 [753] doi:10.1016/j.ebiom.2026.106121 …more. Play ...
doi:10.1016/S0140-6736(26)00202-3 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #semaglutida #diabetes ...
... 10.1016/S0140-6736(26)00202-3. Newsletter. Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of ...
... 26 weeks and weight loss had not plateaued, reaching 11.8% at 36 ... 10.1016/S0140-6736(26)00202-3 [751] doi:10.1002/cpdd.1594 [752] ...
doi:10.1016/S0140-6736(26)00202-3 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #semaglutida #diabetes ...
DOI: 10.1016/S0140-6736(26)00202-3. som original - Dra. Luíza Vercelli. 4Curtidas. 1Comentários. 0Compartilhamentos. nnynnwr. неверли вил. она ...
doi:10.1016/S0140-6736(26)00202-3PubMedGoogle ScholarCrossref. 22. Pfizer. June 26, 2023. Accessed April 24, 2026. https://www.Pfizer.Com ...
DOI: 10.1016/S0140-6736(26)00202-3. som original - Dra. Luíza Vercelli. 4Curtidas. 1Comentários. 0Compartilhamentos. noviraacademy. نوڤيرا ...
DOI: 10.1016/S0140-6736(26)00202-3 #ACHIEVE3 #Orforglipron #Semaglutida #GLP1 #DiabetesTipo2 HbA1c PérdidaDePeso MedicinaBasadaEnEvidencia ...
DOI: 10.1016/S0140-6736(26)00202-3. som original - Dra. Luíza Vercelli. 4Curtidas. 1Comentários. 0Compartilhamentos. drcameliapatru. Clinica Dr ...
... 26, 2026. doi:10.1016/S0140-6736(26)00202-3. [Study 751] Morse BL, Bhattachar S, Ma X, et al. Disposition and absolute bioavailability of ...
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a ...
... 10.1016/S0140-6736(26)00202-3 https://pubmed.ncbi.nlm.nih.gov/41765029/ Rodriguez et al 2024. JAMA 184: 1056-1064. doi: 10.1001 ...
... Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): A ...
) "Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a ...
https://doi.org/10.1016/S0140-6736(23)01302-8; Wharton S, Blevins, T ... 6736(26)00202-3/abstract; Foundayo Prescribing information ...
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a ...
doi:10.1016/S0140-6736(26)00202-3 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #semaglutida #diabetes ...
DOI: 10.1016/S0140-6736(26)00202-3. som original - Dra. Luíza Vercelli. 4Curtidas. 1Comentários. 0Compartilhamentos. luizavercelli. Dra. Luíza ...
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a ...
doi:10.1016/S0140-6736(26)00202-3 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #semaglutida #diabetes ...
doi:10.1016/S0140-6736(26)00202-3 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #semaglutida #diabetes ...
... 26 feb. 2026 DOI: 10.1016/S0140-6736(26)00202-3 • Ensayos ATTAIN-1 y ATTAIN-2 — Programa fase 3, Eli Lilly • SURMOUNT-5 — NEJM DOI: 10.1056 ...
... 10.1016/S0140-6736(26)00202-3 · Wharton S et al. ATTAIN-1. N Engl J Med. 2025;393(18):1796-1806. DOI: 10.1056/NEJMoa2511774 · FDA approval ...
... Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a ...
Endocrine Monthly Round-Up | Pakistan Endocrine Society Stay updated with the latest developments in endocrinology through the monthly ...
... Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a ...
ACHIEVE-3 showed that once-daily oral orforglipron, added to metformin, reduced HbA1c more than 14 mg oral semaglutide at 52 weeks, ...
... 10.1016/S0140-6736(26)00202-3. 5. Wharton S, Freitas P, Hjelmesæth J, et al; STEP UP Trial Group. Once-weekly semaglutide 7·2 mg in adults ...
After weight loss benefits, Eli Lilly's triple‑agonist therapy retatrutide shows promise for type 2 diabetes, delivering A1C reductions of ...
2026:S0140-6736(26)00202-3. doi:10.1016/S0140-6736(26)00202-3. Share this article. facebook share Share on Facebook · twitter share Share on ...
Lancet. 2026 Mar 21;407(10534):1147-1160. doi: 10.1016/S0140-6736(26)00202-3. Epub 2026 Feb 26. 可能是顯示的文字是「 THE ACHIEVE-3 Trial ...
... Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3) #Diabetes ...
Efficacy and safety of once-daily oral orforglipron compared with oral. 25w. 肝炎資訊及病友權益. 而Novo Nordisk 也剛宣布，美FDA 核准較高劑量7.2 ...
doi:10.1016/S0140-6736(26)00202-3 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #semaglutida #diabetes ...
Lancet paper: Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3) ...
Investigate the Efficacy and Safety of Once- Daily Oral Orforglipron Compared with. Placebo in Adult Participants with Obesity or Overweight ...
doi:10.1016/S0140-6736(26)00202-3 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #semaglutida #diabetes ...
... Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3). The Lancet 2026."
ACHIEVE-3: Oral GLP-1 add-on therapy for diabetes management in adults with T2D on metformin, once-daily oral #orforglipron was superior to ...
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a ...
... Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3) Risk factors ...
... Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3) Risk factors ...
New results from ACHIEVE-3: Comparing two GLP-1 RAs in adults with type 2 diabetes. Learn more: https://e.lilly/46unvth.
... Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a ...
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a ...
... 26, 2026. doi:10.1016/s0140-6736(26)00202-3. Newsletter. Join thousands of clinicians staying current on new therapies, trial data, and expert ...
The Lancet. 2026;DOI:10.1016/S0140-6736(26)00202-3. Featured image: Andreas Prott on Adobe Stock.
I dettagli della ricerca “Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes ...
org/10.1016/S0140-6736(26)00202-3. 打印 发E-mail给：. 以下评论只代表网友个人观点，不代表科学网观点。 相关新闻, 相关论文. 1; 小RNA病毒VP2蛋白“ ...
Företaget Eli Lillys orala GLP1-agonist orforglipron gav bättre sänkning av blodsockret än oralt semaglutid hos patienter med typ 2-diabetes ...
https://doi.org/10.1016/S0140-6736(26)00202-3 Anche la Company, Eli Lilly, ha annunciato i risultati dettagliati di ACHIEVE-3. https ...
... 10.1016/S0140-6736(26)00202-3. A Study of Orforglipron (LY3502970) Compared with Semaglutide in Participants with Type 2 Diabetes ...
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a ...
DOI: 10.1016/S0140-6736(26)00202-3. Source: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00202-3/abstract. 期刊信息.
26 Congress ACHIEVE-2, -3, -5 clinical trial program evaluating orforglipron in adults with T2D. Funded by Eli Lilly. Orforglipron is a ...
Lancet 2026;26. doi: 10.1016/S0140-6736(26)00202-3 . 1 the bmj | BMJ 2026;392:s399 | doi: 10.1136/bmj.s399. NEWS. London. Cite this as: BMJ ...
10.1016/S0140-6736(26)00202-3. Method of Research. Randomized controlled/clinical trial. Subject of Research. People. Article Title. Efficacy ...
was published in The Lancet at 11:30am UK time on Thursday 26th February 2026. DOI: https://doi.org/10.1016/S0140-6736(26)00202-3. Declared ...
... 10.1016/S0140-6736(23)01127-3. ACHIEVE-3. DOI: 10.1016/S0140-6736(26)00202-3. OpenHouse Clinic 6th Floor, Park Silom Whatsapp +668 1524 6561
thelancet.com. Efficacy and safety of once-daily oral orforglipron compared with. 6mo. 1. Profile photo of Ng. Ng Michael. 2.2℅ is very minimal.
2026;doi:10.1016/S0140-6736(26)00202-3. “Orforglipron represents a potential new therapeutic option for individuals with type 2 diabetes ...
... 10.1016/ S0140-6736(26)00202-3. Secondary Source. The Lancet. Source Reference: Nauck MA, Horowitz M "Oral GLP-1 receptor agonists ...
... 26, 2026. Accessed February 26, 2026. doi:10.1016/S0140-6736(26)00202-3. 3. FDA awards second batch of national priority vouchers. News ...
Efficacy and safety of once-daily oral orforglipron compared with oral. 18w · 1 like. Ng Michael. 2.2℅ is very minimal... 18w. 生醫前線觀察員的 ...
Personally, I am optimistic that this innovation may open a new chapter in incretin-based therapy. Efficacy and safety of once-daily oral ...
Efficacy and safety of once-daily oral ...
Orforglipron will be important, although lower doses might be required for many patients. Efficacy and safety of once-daily oral ...
Personally, I am optimistic that this innovation may open a new chapter in incretin-based therapy. Efficacy and safety of once-daily oral ...
Orforglipron will be important, although lower doses might be required for many patients. Efficacy and safety of once-daily oral ...
Orforglipron will be important, although lower doses might be required for many patients. Efficacy and safety of once-daily oral ...
Personally, I am optimistic that this innovation may open a new chapter in incretin-based therapy. Efficacy and safety of once-daily oral ...
doi:10.1016/S0140-6736(26)00202-3 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #semaglutida #diabetes ...
doi:10.1016/S0140-6736(26)00202-3 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #semaglutida #diabetes ...
doi: 10.1016/S0140-6736(26)00202-3 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #semaglutida ...
doi:10.1016/S0140-6736(26)00202-3 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #semaglutida #diabetes ...
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a ...
2026;407:1147-1160. DOI: 10.1016/S0140-6736(26)00202-3 #ACHIEVE3 #Orforglipron #Semaglutida #GLP1 #DiabetesTipo2 EfectosAdversos Seguridad ...
... 26 % menos infartos no fatales ✓ Menor frecuencia de derrames ... doi:10.1016/S0140-6736(26)00202-3 ℹ️ Contenido educativo. No ...
DOI: 10.1016/S0140-6736(26)00202-3. Você acha que a metformina continuará ocupando o mesmo espaço nos próximos 10 anos? Salve e ...
... Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Adult Participants With Obesity or Overweight With Weight ...
[750] doi:10.1016/S0140-6736(26)00202-3 [751] doi:10.1002/cpdd.1594 ... SOLSTICE Trial (Type 2 Diabetes): Achieved an average 1.9% HbA1c reduction ...
2026;407:1147-1160. DOI: 10.1016/S0140-6736(26)00202-3 #ACHIEVE3 #Orforglipron #Semaglutida #GLP1 #DiabetesTipo2 EfectosAdversos Seguridad ...
doi: 10.1016/S0140-6736(26)00202-3 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #semaglutida ...
10.1016/S0140-6736(26)00202-3; Sloop KW, Cox AL, Wainscott DB, et al.: The pharmacological basis for nonpeptide agonism of the GLP-1 receptor ...
DB
大筋
AM
RD
BM
DJ
LP
JO
DQ
Tで
GS
YL
JE
DV
DE
MT
CT
UR
R
た
TW
RM
CM
SU
SU